Predictors of long-term mortality in new start statin users

Figures & data

Table 1. Baseline demographics.

Characteristic	Survival group (n = 4160)	Mortality group (n = 402)	p Value
Age (years), mean in years (SD)	62.61 (10.65)	71.35 (10.68)	<0.001
Male sex, n (%)	3971 (95.5%)	395 (98.3%)	0.008
Ethnicity (Hispanic), n (%)	485 (11.7%)	23 (5.7%)	<0.001
Race, n (%)			0.002
White	2430 (58.4%)	271 (67.4%)
Black or African American	592 (14.2%)	50 (12.4%)
Asian	165 (3.97%)	6 (1.49%)
American Indian or Alaska Native	59 (1.42%)	2 (0.50%)
Unknown	914 (22.0%)	73 (18.2%)
BMI (kg/m^2)	30.30 (5.65)	29.22 (6.09)	<0.001
Obese, BMI >30, n (%)	1902 (45.7%)	150 (37.3%)	0.001
MPR, mean (SD)	0.73 (0.256)	0.75 (0.245)	0.11
Start medication count	7.20 (4.37)	9.10 (4.73)	<0.001
Total cholesterol (mg/dL), mean (SD)	214.20 (46.27)	202.21 (47.30)	<0.001
Low-density lipoprotein (mg/dL), mean (SD)	138.47 (39.20)	126.65 (37.97)	<0.001
High-density lipoprotein (mg/dL), mean (SD)	42.41 (11.90)	41.19 (12.71)	0.05
Triglycerides (mg/dL), mean (SD)	170.47 (143.86)	174.88 (160.50)	0.57
Hypertension	2970 (71.4%)	340 (84.6%)	<0.001
Diabetes	1548 (37.2%)	185 (46.0%)	0.001
Vascular disease	1281 (30.8%)	196 (48.8%)	<0.001
Tobacco use	1197 (28.8%)	125 (31.1%)	0.33
Alcohol abuse history	772 (18.6%)	66 (16.4%)	0.29
Erectile dysfunction	657 (15.8%)	75 (18.7%)	0.14
Chronic obstructive pulmonary disease	354 (8.5%)	92 (22.9%)	<0.001
High potent statin	281 (6.75%)	33 (8.2%)	0.27
Congestive heart failure	159 (3.8%)	50 (12.4%)	<0.001
History of myocardial infarction	104 (2.5%)	23 (5.7%)	<0.001
Angina	89 (2.14%)	17 (4.2%)	0.008
Bipolar	70 (1.68%)	5 (1.24%)	0.51

Table 2. Odds ratios of mortality via logistic regression.

Variable	Odds ratio (95% CI)	p Value
Age	1.08 (1.07, 1.09)	<0.001*
Male	1.54 (0.69, 3.44)	0.29
Ethnicity (Hispanic)	0.52 (0.33, 0.83)	0.005*
Race
White	Ref
Black or African American	0.75 (0.52, 1.06)	0.10
Asian	0.41 (0.17, 0.99)	0.047*
American Indian or Alaska Native	0.28 (0.07, 1.18)	0.08
Unknown	0.67 (0.50, 0.89)	0.006*
BMI follow-up
<25.0	Ref
25.0–29.9	0.68 (0.51, 0.90)	0.008*
30.0–34.9	0.59 (0.42, 0.83)	0.002*
≥35.0	0.77 (0.53, 1.12)	0.17
Annual Zip Code Income, by Quintile
Quintile 1 (Lowest Income)	Ref
Quintile 2	1.11 (0.78, 1.57)	0.56
Quintile 3	1.17 (0.83, 1.66)	0.38
Quintile 4	0.93 (0.65, 1.34)	0.70
Quintile 5 (Highest Income)	1.05 (0.74, 1.50)	0.79
LDL follow-up
<70	Ref
70–99	0.87 (0.63, 1.20)	0.39
100–129	0.80 (0.56, 1.14)	0.22
130–159	0.87 (0.57, 1.32)	0.50
≥160	1.07 (0.66, 1.73)	0.79
End Medication Count	1.04 (1.02, 1.07)	0.001*
Hypertension	1.46 (1.08, 1.98)	0.015*
Diabetes	1.36 (1.07, 1.72)	0.012*
Vascular disease	1.21 (0.96, 1.53)	0.11
Tobacco use	1.52 (1.16, 1.99)	0.002
Alcohol abuse history	1.24 (0.91, 1.70)	0.18
Erectile dysfunction	1.01 (0.76, 1.34)	0.97
Chronic obstructive pulmonary disease	1.88 (1.40, 2.53)	<0.001*
Congestive heart failure	1.80 (1.23, 2.63)	0.002*
Angina	1.02 (0.57, 1.85)	0.94
Bipolar	0.87 (0.33, 2.31)	0.79

*Statistical significance.

Figure 1. Study inclusion and exclusion flowchart.